methyl 3-cyclopropyl-3-methylbutanoate | 486394-55-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 3-cyclopropyl-3-methylbutanoate
• CAS: 486394-55-2
• 化学式: C₉H₁₆O₂
• 分子量: 156.225
• InChiKey: VLAPDKFWDLHLKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 3-cyclopropyl-3-methylbutanoate 在 sodium hydroxide 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 (+)-8,8-二氯樟脑磺哑嗪 、 N,N-二异丙基乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl N-[[4-chloro-2-[[[(2S)-1-[(2R)-3-cyclopropyl-2-hydroxy-3-methylbutanoyl]azetidine-2-carbonyl]amino]methyl]phenyl]methyl]carbamate
  参考文献：
  名称：

  Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability

  摘要：

  Modification of lead compound 1 by reducing lipophilicity in the P3 group produced a series of low molecular weight thrombin inhibitors with excellent potency in functional assays, metabolic stability, and oral bioavailability. These modifications led to the identification of two optimized compounds, 14 and 16. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.030
• 作为产物：
  描述：

  重氮甲烷 、 3,3-二甲基-4-戊烯酸甲酯 在 palladium diacetate 作用下， 以 乙醚 为溶剂， 生成 methyl 3-cyclopropyl-3-methylbutanoate
  参考文献：
  名称：

  Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability

  摘要：

  Modification of lead compound 1 by reducing lipophilicity in the P3 group produced a series of low molecular weight thrombin inhibitors with excellent potency in functional assays, metabolic stability, and oral bioavailability. These modifications led to the identification of two optimized compounds, 14 and 16. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.030

文献信息

• Thrombin inhibitors
  申请人：——

  公开号：US20030013700A1

  公开（公告）日：2003-01-16

  Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: 1 or a pharmaceutically acceptable salt thereof, e.g. 1-(3(S)-Cyclopropyl-2(R)-hydroxybutanoyl)azetidine-2(S)-N-(2-aminomethyl-5-chlorobenzyl)carboxamide, and 1-(3-Cyclopropyl-3-methyl-2(R)-hydroxybutanoyl)azetidine-2(S)-N-(2-aminomethyl-5-chlorobenzyl)carboxamide.

  该发明的化合物可用于抑制凝血酶和相关的血栓闭塞，具有以下结构：1或其药学上可接受的盐，例如1-(3(S)-环丙基-2(R)-羟基丁酰)氮杂环丙烷-2(S)-N-(2-氨基甲基-5-氯苯甲基)羧酰胺，和1-(3-环丙基-3-甲基-2(R)-羟基丁酰)氮杂环丙烷-2(S)-N-(2-氨基甲基-5-氯苯甲基)羧酰胺。
• US6528503B2
  申请人：——

  公开号：US6528503B2

  公开（公告）日：2003-03-04
• Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability
  作者：Matthew M Morrissette、Kenneth J Stauffer、Peter D Williams、Terry A Lyle、Joseph P Vacca、Julie A Krueger、S.Dale Lewis、Bobby J Lucas、Bradley K Wong、Rebecca B White、Cynthia Miller-Stein、Elizabeth A Lyle、Audrey A Wallace、Yvonne M Leonard、Denise C Welsh、Joseph J Lynch、Daniel R McMasters

  DOI：10.1016/j.bmcl.2004.06.030

  日期：2004.8

  Modification of lead compound 1 by reducing lipophilicity in the P3 group produced a series of low molecular weight thrombin inhibitors with excellent potency in functional assays, metabolic stability, and oral bioavailability. These modifications led to the identification of two optimized compounds, 14 and 16. (C) 2004 Elsevier Ltd. All rights reserved.